← Back to Home

FDA Expands Approval of Prostate Cancer Combination Therapy, Reducing Risk of Radiographic Progression by 52% in Patients With HRR Mutations

Talazoparib combined with enzalutamide adds a treatment option for patients with metastatic prostate cancer carrying specific gene mutations. A trial involving 599 patients showed longer disease control, but whether the combination extends life awaits more mature follow-up data.

By SURL BioNews

For some patients whose prostate cancer has metastasized and remains hormone-sensitive, genetic testing now has another direct implication for treatment selection. On October 26, the US Food and Drug Administration (FDA) approved talazoparib combined with enzalutamide for adults with metastatic prostate cancer carrying homologous recombination repair (HRR) gene mutations who have not received androgen pathway–modulating therapy or remain sensitive to it.

The approval has specific molecular selection criteria and does not apply to all patients with metastatic disease. Patients must have an HRR gene mutation confirmed by an FDA-authorized test. The FDA also noted that FoundationOne CDx and FoundationOne Liquid CDx had previously been approved as companion diagnostics for this combination therapy. The trial supporting approval used tumor tissue or circulating tumor DNA in blood to confirm mutation status in genes including BRCA1 and BRCA2.

The efficacy evidence comes from TALAPRO-3, a randomized, double-blind, placebo-controlled trial. The 599 eligible patients were divided into two groups receiving either talazoparib plus enzalutamide or placebo plus enzalutamide; all patients also continued androgen deprivation therapy. The trial therefore examined whether adding talazoparib to existing hormone therapy could further delay disease progression.

The results showed that the combination therapy group had a 52% lower risk of radiographic progression or death than the control group, with a hazard ratio of 0.48 (95% confidence interval, 0.36 to 0.65; P < 0.0001). Median radiographic progression-free survival was 45.8 months in the control group and had not yet been reached in the combination therapy group, meaning that fewer than half of patients in that group had experienced this composite endpoint event at the time of analysis.

This represents progress in disease control, but it does not yet establish that patients live longer. Both the FDA announcement and reporting by The ASCO Post noted that overall survival data were still immature at the time of analysis. In addition, the overall trial results cannot be directly interpreted as showing the same degree of benefit for every type of HRR gene mutation.

Treatment benefits must also be weighed against toxicity. A summary from the Oncology Nursing Society noted that the recommended talazoparib dose is 0.5 mg orally once daily, combined with enzalutamide, until disease progression or unacceptable toxicity. Patients must also continue treatment with a GnRH analog or have previously undergone bilateral orchiectomy. The prescribing information includes warnings for myelosuppression, myelodysplastic syndrome/acute myeloid leukemia, and embryo-fetal toxicity, indicating that blood-related toxicity is also an important aspect of care as disease control is extended.

The application received FDA priority review and was reviewed collaboratively with Australia’s Therapeutic Goods Administration and Health Canada through Project Orbis; reviews by the latter two regulators were still ongoing at the time of the announcement. The US approval has added an option for patients who meet the genetic criteria, while long-term survival follow-up will further clarify the extent of sustained benefit from using this combination therapy earlier.

References

  1. FDA
  2. The ASCO Post
  3. Oncology Nursing Society